10.1002/cmdc.202000222
ChemMedChem
FULL PAPER
Chemistry
2-Cyclopentyl-N'-[(1E)-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl-
oxy)benzylidene]acetohydrazide (Acetylated A1H8)
Compounds 1 and 4 were purchased. Compounds 2,[39] 3,[40,41] 5,[27] 6,[42,43]
and 7[40] were prepared according to reported procedures.
The acylhydrazone was synthesized according to GP1 by using 2-
chlorophenoxyacetic acid hydrazide (18.9 mg, 0.13 mmol) in MeOH (1.8
mL) and p-(tetraacetyl-β-D-glucopyranosyl)benzaldehyde 3 (50.0 mg, 0.11
mmol). After purification, the acylhydrazone was obtained as a white solid
(59 mg, 93%). 1H-NMR (500 MHz, CD3OD) δ 8.05 (s, 1Htrans), 7.89 (s,
1Hcis), 7.75 (d, J = 8.8 Hz, 2Htrans), 7.63 (d, J = 8.8 Hz, 2Hcis), 7.07 (d,
J = 8.8 Hz, 2Htrans, 2Hcis), 5.46 – 5.35 (m, 2Htrans, 2Hcis), 5.22 – 5.07
(m, 2Htrans, 2Hcis), 4.39 – 4.24 (m, 1Htrans, 1Hcis), 4.21 – 4.01 (m,
2Htrans, 2Hcis), 2.74 (d, J = 7.4 Hz, 2Hcis), 2.40 – 2.12 (m, 3Htrans,
1Hcis), 2.10 – 1.93 (m, 12Htrans, 12Hcis), 1.91 – 1.78 (m, 2Htrans, 2Hcis),
1.77 – 1.53 (m, 4Htrans, 4Hcis), 1.38 – 1.16 (m, 2Htrans, 2Hcis); 13C-NMR
(126 MHz, CD3OD) δ 177.6, 172.4 (2C), 172.3 (2C), 171.6, 171.3 (2C),
171.1 (2C), 160.2, 159.9, 148.6, 144.8, 130.4 (2C), 130.3 (2C), 129.5 (2C),
117.9 (2C), 117.8 (2C), 99.2, 99.1, 74.1 (2C), 73.1 (2C), 72.7 (2C), 69.7
(2C), 63.1, 63.0, 41.6, 39.4, 38.6, 38.0, 33.5 (2C), 33.4 (2C), 25.9 (4C),
20.6 (4C), 20.5 (4C); HRMS (ESI) calcd for C28H37N2O11 [M+H]+: 577.2397,
found: 577.2360.
4-(β-D-Glucopyranosyloxy)benzaldehyde (A1)
Compound A1 was synthesized by a slight modification of the reported
method.[44] p-(Tetraacetyl-β-D-glucopyranosyl)benzaldehyde 3[40,41] (225
mg, 0.5 mmol) was dissolved in 3 mL dry MeOH in a flame-dried flask
under nitrogen. Next, a methanolic NaOMe solution (1.5 M, 0.5 mL) was
added dropwise, and the reaction was stirred for 4 h at room temperature.
The reaction was neutralized with DOWEX 50WX8 hydrogen-form ion
exchange resin, filtered and passed through a pad of charcoal to remove
any colored impurities and then evaporated to dryness in vacuo to obtain
pure compound A1 (137 mg, quantitative). NMR spectra show that A1 is
present as a hydrate form in the NMR solvent. 1H-NMR (400 MHz, CD3OD)
δ 7.34 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.7 Hz, 2H), 5.33 (s, 1H), 4.94 –
4.90 (m, 1H), 3.89 (dd, J = 12.0, 2.1 Hz, 1H), 3.69 (dd, J = 12.0, 5.4 Hz,
1H), 3.50 – 3.29 (m, 4H); 13C-NMR (101 MHz, CD3OD) δ 159.2, 133.5,
129.0 (2C), 117.3 (2C), 104.2, 102.2, 78.2, 78.0, 74.9, 71.4, 62.5; HRMS
(ESI) calcd for C13H15O7 [M–H]–: 283.0823, found: 283.0822.
4-(4-O-α-D-Glucopyranosyl-β-D-glucopyranosyloxy)benzaldehyde
(A2)
2-Cyclopentyl-N'-[(1E)-4-(β-D-glucopyranosyloxy)benzylidene]aceto-
hydrazide (A1H8)
p-(Heptaacetyl-β-D-maltosyl)benzaldehyde 7[40] (340.7 mg, 0.46 mmol)
was dissolved in 5 mL dry MeOH in a flame-dried flask under nitrogen.
Next, a methanolic NaOMe solution (1.5 M, 1 mL) was added dropwise,
and the reaction was stirred for 4 h at room temperature. The reaction was
neutralized with DOWEX 50WX8 hydrogen-form ion exchange resin,
filtered and passed through a pad of charcoal to remove any colored
impurities and then evaporated to dryness in vacuo to obtain pure
compound A2 (142 mg, 70%). 1H NMR (400 MHz, CD3OD) δ 9.84 (s, 1H),
7.87 (d, J = 8.7 Hz, 2H), 7.34 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H),
7.08 (d, J = 8.7 Hz, 2H), 5.32 (s, 1H), 5.21 (t, J = 3.4 Hz, 2H), 5.09 (d, J =
7.8 Hz, 1H), 4.96 (d, J = 7.8 Hz, 1H), 3.96 – 3.43 (m, 22H), 3.32 – 3.25 (m,
2H); 13C NMR (101 MHz, CD3OD) δ 193.1, 163.8 (2C), 159.0 (2C), 133.4,
132.9, 132.4, 128.9, 117.8 (2C), 117.2 (2C), 104.3, 102.7 (2C), 101.9,
101.2, 80.7, 80.5, 77.6, 77.5, 76.8, 76.6, 75.0 (2C), 74.7 (2C), 74.4, 74.3,
74.0 (2C), 71.4 (2C), 62.6 (2C), 61.9 (2C); HRMS (ESI) calcd for C19H25O12
[M–H]–: 445.1346, found: 445.1353.
The acylhydrazone was synthesized according to GP2 by using compound
acetylated A1H8 (23.0 mg, 0.04 mmol) in MeOH (4 mL) and sodium
methoxide (0.32 mg, 0.006 mmol). After purification, the acylhydrazone
was obtained as a white solid (13 mg, 82%). 1H-NMR (500 MHz, CD3OD)
δ 8.05 (s, 1Htrans), 7.88 (s, 1Hcis), 7.73 (d, J = 8.8 Hz, 2Htrans), 7.61 (d,
J = 8.8 Hz, 2Hcis), 7.23 – 7.02 (m, 2Htrans, 2Hcis), 4.98 – 4.95 (m, 1Htrans,
1Hcis), 3.93 – 3.87 (m, 1Htrans, 1Hcis), 3.74 – 3.66 (m, 1Htrans, 1Hcis),
3.52 – 3.36 (m, 4Htrans, 4Hcis), 2.74 (d, J = 7.5 Hz, 2Hcis), 2.43 – 2.23
(m, 3Htrans, 1Hcis), 1.92 – 1.77 (m, 2Htrans, 2Hcis), 1.75 – 1.52 (m,
4Htrans, 4Hcis), 1.41 – 1.09 (m, 2Htrans, 2Hcis); 13C-NMR (126 MHz,
CD3OD) δ 177.5, 172.3, 160.9, 160.6, 149.0, 145.2, 130.2 (2C), 129.9 (2C),
129.6, 129.4, 117.9 (2C), 117.8 (2C), 101.9 (2C), 78.2 (2C), 78.0, 77.9,
74.9 (2C), 71.3 (2C), 62.5 (2C), 41.6, 39.4, 38.5, 38.0, 33.5 (2C), 33.4 (2C),
25.9 (4C); HRMS (ESI) calcd for C20H29N2O7 [M+H]+: 409.1975, found:
409.1964.
2-(2-Chlorophenoxy)-N'-[(1E)-4-(2,3,4,6-tetra-O-acetyl-β-D-gluco-
pyranosyloxy)benzylidene]acetohydrazide (Acetylated A1H12)
The acylhydrazone was synthesized according to GP1 by using 2-
chlorophenoxyacetic acid hydrazide (26.6 mg, 0.13 mmol) in MeOH (1.8
mL) and p-(tetraacetyl-β-D-glucopyranosyl)benzaldehyde 3 (50.0 mg, 0.11
mmol). After purification, the acylhydrazone was obtained as a white solid
(43 mg, 61%). 1H-NMR (500 MHz, CD3OD) δ 8.19 (s, 1Htrans), 7.93 (s,
1Hcis), 7.77 (d, J = 8.8 Hz, 2Htrans), 7.66 (d, J = 8.8 Hz, 2Hcis), 7.43 –
7.36 (m, 1Htrans, 1Hcis), 7.33 – 7.19 (m, 1Htrans, 1Hcis), 7.14 – 6.90 (m,
4Htrans, 4Hcis), 5.44 – 5.34 (m, 2Htrans, 2Hcis), 5.25 (s, 2Hcis), 5.21 –
5.15 (m, 1Htrans, 1Hcis), 5.15 – 5.09 (m, 1Htrans, 1Hcis), 4.76 (s, 2Htrans),
4.35 – 4.27 (m, 1Htrans, 1Hcis), 4.21 – 4.06 (m, 2Htrans, 2Hcis), 2.19 –
1.76 (m, 12Htrans, 12Hcis); 13C-NMR (126 MHz, CD3OD) δ 172.3 (2C),
171.6 (2C), 171.4, 171.3 (2C), 171.1 (2C), 167.1, 160.1, 159.8, 155.5,
155.0, 150.6 (2C), 146.1 (2C), 131.5, 131.4, 130.6, 130.3, 130.1, 129.8,
129.3, 128.9, 124.4, 124.1, 124.0, 123.1, 117.9, 117.8, 116.1, 115.3, 99.1
(2C), 74.1 (2C), 73.1 (2C), 72.6 (2C), 69.7, 69.6, 69.2 (2C), 67.3 (2C), 63.1,
63.0, 20.6 (4C), 20.5 (4C); HRMS (ESI) calcd for C29H32ClN2O12 [M+H]+:
635.1644, found: 635.1638.
General procedure for acylhydrazone formation (GP1):[36]
To the hydrazide (1 equiv) dissolved in MeOH, the corresponding aldehyde
(1.2 equiv) was added. The reaction mixture was stirred at room
temperature or refluxed until completion. After cooling to room temperature,
the reaction mixture was concentrated in vacuo. Purification of acetylated
products was performed by column chromatography and deprotected
sugars were purified by preparative HPLC, affording the corresponding
acylhydrazone in 60% to quantitative yields.
General procedure for the deprotection of the acetyl groups (GP2):[26]
The classical Zemplén deacetylation method of the O-acetyl protecting
groups with sodium methoxide in MeOH at room temperature was used.
The O-acetyl protected sugar was dissolved in MeOH (0.01 M), and a
catalytic amount of sodium methoxide (0.15 equiv) was added. The
reaction mixture was stirred at room temperature until complete
deprotection was achieved.
tert-Butyl 4-({(2E)-2-[4-(β-D-glucopyranosyloxy)benzylidene]hydra-
zino}carbonyl)piperidine-1-carboxylate (A1H2)
The acylhydrazone was synthesized according to GP1 by using 1-Boc-
isonipecotic acid hydrazide (26 mg, 0.1 mmol) in MeOH (1.0 mL) and p-
(β-D-glucopyranosyloxy)benzaldehyde A1 (14.5 mg, 0.05 mmol). After
purification, the acylhydrazone was obtained as a white solid (12 mg, 46%).
1H-NMR (500 MHz, CD3OD) δ 8.05 (s, 1Htrans), 7.88 (s, 1Hcis), 7.70 (d,
J = 8.6 Hz, 2Htrans), 7.60 (d, J = 8.6 Hz, 2Hcis), 7.15 – 7.06 (m, 2Htrans,
2Hcis), 4.98 – 4.92 (m, 1Htrans, 1Hcis), 4.12 (d, J = 13.3 Hz, 2Htrans,
2Hcis), 3.92 – 3.84 (m, 1Htrans, 1Hcis), 3.69 (dd, J = 12.1, 5.6 Hz, 1Htrans,
1Hcis), 3.51 – 3.34 (m, 6Htrans, 7Hcis), 2.45 (tt, J = 11.4, 3.6 Hz, 1Htrans),
1.89 – 1.52 (m, 4Htrans, 4Hcis), 1.45 (s, 9Htrans, 9Hcis); 13C-NMR (126
MHz, CD3OD) δ 178.6, 173.9, 161.0, 160.6, 156.5, 156.4, 149.3, 145.5,
130.2 (2C), 129.8 (2C), 129.5 (2C), 117.9 (2C), 117.8 (2C), 101.9 (2C),
81.2, 81.1, 78.2 (2C), 78.0, 77.9, 74.8 (2C), 71.3 (2C), 62.5 (2C), 49.8 (2C),
42.7 (2C), 39.5 (2C), 29.5 (2C), 28.9 (2C), 28.7 (6C); HRMS (ESI) calcd
for C24H36N3O9 [M+H]+: 510.2452, found: 510.2432.
2-(2-Chlorophenoxy)-N'-[(1E)-4-(β-D-glucopyranosyloxy)benzyl-
idene]acetohydrazide (A1H12)
The acylhydrazone was synthesized according to GP2 by using
acetylated A1H12 (26.1 mg, 0.04 mmol) in MeOH (4 mL) and sodium
methoxide (0.33 mg, 0.006 mmol). After purification, the acylhydrazone
1
was obtained as a white solid in quantitative yield (20 mg). H-NMR (500
MHz, DMSO-d6) δ 11.54 (br s, NH, 1Htrans, 1Hcis), 8.22 (s, 1Hcis), 7.96
(s, 1Htrans), 7.70 – 7.60 (m, 2Htrans, 2Hcis), 7.49 – 7.37 (m, 1Htrans,
1Hcis), 7.34 – 7.20 (m, 1Htrans, 1Hcis), 7.12 – 6.89 (m, 4Htrans, 4Hcis),
5.37 (br s, OH, 1Htrans, 1Hcis), 5.25 (s, 2Htrans), 5.16 (br s, OH, 1Htrans,
1Hcis), 5.08 (br s, OH, 1Htrans, 1Hcis), 4.96 – 4.88 (m, 1Htrans, 1Hcis),
4.74 (s, 2Hcis), 4.58 (br s, OH, 1Htrans, 1Hcis), 3.69 (d, J = 11.3 Hz,
1Htrans, 1Hcis), 3.53 – 3.41 (m, 1Htrans, 1Hcis), 3.39 – 3.11 (m, 4Htrans,
4Hcis);13C-NMR (126 MHz, DMSO-d6) δ 168.4, 158.7, 153.7, 153.5, 143.6
7
This article is protected by copyright. All rights reserved.